Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.

Wissing MD, Dadon T, Kim E, Piontek KB, Shim JS, Kaelber NS, Liu JO, Kachhap SK, Nelkin BD.

Oncol Rep. 2014 Jul;32(1):419-24. doi: 10.3892/or.2014.3174. Epub 2014 May 13.

2.

RNAi-mediated knockdown of pituitary tumor- transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells.

Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen SX, Wu QJ, Ye G.

Braz J Med Biol Res. 2012 Nov;45(11):995-1001. Epub 2012 Aug 9.

3.

All-trans retinoic acid induces DU145 cell cycle arrest through Cdk5 activation.

Lin E, Chen MC, Huang CY, Hsu SL, Huang WJ, Lin MS, Wu JC, Lin H.

Cell Physiol Biochem. 2014;33(6):1620-30. doi: 10.1159/000358724. Epub 2014 May 16.

4.

Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.

Hsu FN, Chen MC, Lin KC, Peng YT, Li PC, Lin E, Chiang MC, Hsieh JT, Lin H.

Am J Physiol Endocrinol Metab. 2013 Oct 15;305(8):E975-86. doi: 10.1152/ajpendo.00615.2012. Epub 2013 Aug 13.

PMID:
23941877
5.

Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells.

Xu P, Cai F, Liu X, Guo L.

Oncol Rep. 2015 Jun;33(6):3117-23. doi: 10.3892/or.2015.3888. Epub 2015 Mar 31.

PMID:
25845399
6.

Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells.

Wang P, Liu B, Luo JD, Zhang ZG, Ma Q, Chen ZD.

Asian J Androl. 2007 May;9(3):353-60.

7.

Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5.

Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH, Lee GS, Lin H.

J Biol Chem. 2011 Sep 23;286(38):33141-9. doi: 10.1074/jbc.M111.252080. Epub 2011 Jul 28.

8.

Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21.

Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL.

PLoS One. 2013 Aug 1;8(8):e70442. doi: 10.1371/journal.pone.0070442. Print 2013.

9.

Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.

PLoS One. 2013;8(3):e58267. doi: 10.1371/journal.pone.0058267. Epub 2013 Mar 4.

10.

Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.

Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD.

Cancer Res. 2006 Aug 1;66(15):7509-15.

11.

Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis.

Cao L, Zhou J, Zhang J, Wu S, Yang X, Zhao X, Li H, Luo M, Yu Q, Lin G, Lin H, Xie J, Li P, Hu X, Zheng C, Bu G, Zhang YW, Xu H, Yang Y, Huang C, Zhang J.

Clin Cancer Res. 2015 Mar 15;21(6):1419-28. doi: 10.1158/1078-0432.CCR-14-1950. Epub 2015 Jan 21.

12.
14.

Talin1 phosphorylation activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis.

Jin JK, Tien PC, Cheng CJ, Song JH, Huang C, Lin SH, Gallick GE.

Oncogene. 2015 Apr 2;34(14):1811-21. doi: 10.1038/onc.2014.116. Epub 2014 May 5.

15.

Fangchinoline induced G1/S arrest by modulating expression of p27, PCNA, and cyclin D in human prostate carcinoma cancer PC3 cells and tumor xenograft.

Wang CD, Huang JG, Gao X, Li Y, Zhou SY, Yan X, Zou A, Chang JL, Wang YS, Yang GX, He GY.

Biosci Biotechnol Biochem. 2010;74(3):488-93. Epub 2010 Mar 7.

16.

An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.

Xu S, Zhang Z, Ogawa O, Yoshikawa T, Sakamoto H, Shibasaki N, Goto T, Wang L, Terada N.

Cell Biochem Biophys. 2014 Sep;70(1):521-7. doi: 10.1007/s12013-014-9951-2.

PMID:
24744183
17.

Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.

Bonaccorsi L, Marchiani S, Ferruzzi P, Muratori M, Crescioli C, Forti G, Maggi M, Baldi E.

Steroids. 2006 Apr;71(4):304-9. Epub 2005 Nov 9. Review.

PMID:
16289173
18.

EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).

Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G, Baldi E.

Int J Cancer. 2004 Oct 20;112(1):78-86.

19.

A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.

Shi M, Zhou X, Zhang Z, Wang M, Chen G, Han K, Cao B, Liu Z, Mao X.

Toxicol Lett. 2014 Aug 4;228(3):133-9. doi: 10.1016/j.toxlet.2014.05.003. Epub 2014 May 14.

PMID:
24831963
20.

Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.

Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein LE, Härkönen P, Persson JL.

J Natl Cancer Inst. 2008 Jul 16;100(14):1022-36. doi: 10.1093/jnci/djn214. Epub 2008 Jul 8.

Supplemental Content

Support Center